Margareth Ozelo

Danish healthcare giant Novo Nordisk A/S (ADR) (NYSE: NVO) has developed NovoEight for the treatment and prevention of bleeding in patients with haemophilia A. NovoEight, which has already been launched in 11 countries including in the U.S., is a B-domain truncated recombinant human coagulation...